RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Pulmonary Arterial Hypertension: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Right Ventricular Shear Wave Velocity Throughout the Cardiac Cycle in Pediatric Pulmonary Hypertension.
Venet Maelys et al., European heart journal. Cardiovascular Imaging (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895259/
- 2.
Pulmonary hypertension in thalassaemia: a systematic review and meta-analysis of prevalence and risk factors
Yara El Deghel et al., Open Science Framework (18 October 2026)
https://doi.org/10.17605/osf.io/vyjp6
- 3.
Nurses’ Knowledge and Practices regarding Neonates with Persistent Pulmonary Hypertension: An Assessment Study
Rahma Bahgat et al., Tanta Scientific Nursing Journal (18 October 2026)
https://doi.org/10.21608/tsnj.2026.534061
- 4.
Bridging the gap in pulmonary hypertension care: Real-world registry data driving early detection and outcome improvement in Malaysia
K. Kolanthaivelu et al., International Journal of Cardiology (17 October 2026)
https://doi.org/10.1016/j.ijcard.2026.134907
- 5.
Clinical Profile of Echocardiographically Estimated Pulmonary Hypertension in Patients with Non Dialysis-dependent Chronic Kidney Disease Stages 3-5: A Cross-sectional Study
Gunishetti Adithya et al., JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (17 October 2026)
https://doi.org/10.7860/jcdr/2026/91602.24619
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981 · Recruiting · Phase 3 · Insmed Incorporated
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07481981
- 2.
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
NCT07623525 · Recruiting · Phase 1 / Phase 2 · Diagonal Therapeutics, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07623525
- 3.
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597 · Recruiting · Phase 2 · Regeneron Pharmaceuticals
Ages 18 and over
https://clinicaltrials.gov/study/NCT07318597
- 4.
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 · Recruiting · Phase 3 · Inhibikase Therapeutics
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07365332
- 5.
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
NCT07175038 · Recruiting · Phase 2 · AllRock Bio, Inc.
Ages 18 to 80
https://clinicaltrials.gov/study/NCT07175038
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a rare, progressive condition causing high blood pressure in the arteries supplying the lungs, leading to right heart failure. It predominantly affects women. While there is no cure, a growing number of targeted therapies can slow progression and improve symptoms.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Pulmonary Arterial Hypertension?
Pulmonary arterial hypertension is a rare, progressive condition causing high blood pressure in the arteries supplying the lungs, leading to right heart failure. It predominantly affects women. While there is no cure, a growing number of targeted therapies can slow progression and improve symptoms.
How many clinical trials are available for Pulmonary Arterial Hypertension?
RareWays currently indexes 745 clinical trials for Pulmonary Arterial Hypertension, of which 69 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Pulmonary Arterial Hypertension come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Pulmonary Arterial Hypertension.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.